LexDanaLexDanabeta
Inventor

GUOZHI TANG

Inventor
CN

Overview

5→
Patents
2022–2025
Patent span
Human necessities
Primary field (CPC A)

Patents· 5 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations38%
C07DHeterocyclic compounds38%
A61KPreparations for medical, dental or toiletry purposes15%
C07CAcyclic or carbocyclic compounds8%
PatentTitleYear
12,319,703Macrocyclic fused pyrazoles as Mcl-1 inhibitors202511,987,575Tricyclic compounds as BCR-ABL inhibitors202411,691,989Macrocyclic indoles as Mcl-1 inhibitors202311,498,928Macrocyclic spiroethers as Mcl-1 inhibitors202211,312,724Spirocyclic tetrahydroquinazolines2022

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2022–2025Patents assigned to ASCENTAGE PHARMA GROUP CORP LTD (5)· patent assignee history
2022–2025Patents assigned to ASCENTAGE PHARMA SUZHOU CO LTD (5)· patent assignee history
2022–2025Patents assigned to UNIV MICHIGAN REGENTS (3)· patent assignee history
2022–2025Based in CN· patent location history
2025Patents assigned to UNIV MICHIGAN (1)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
ASCENTAGE PHARMA GROUP CORP LTD52022–2025
ASCENTAGE PHARMA SUZHOU CO LTD52022–2025
UNIV MICHIGAN REGENTS32022–2025
UNIV MICHIGAN12025
Locations
LocationPatentsSpan
CN52022–2025